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Immunoinformatics design 
of a novel epitope‑based vaccine 
candidate against dengue virus
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Dengue poses a global health threat, which will persist without therapeutic intervention. Immunity 
induced by exposure to one serotype does not confer long‑term protection against secondary 
infection with other serotypes and is potentially capable of enhancing this infection. Although 
vaccination is believed to induce durable and protective responses against all the dengue virus (DENV) 
serotypes in order to reduce the burden posed by this virus, the development of a safe and efficacious 
vaccine remains a challenge. Immunoinformatics and computational vaccinology have been utilized 
in studies of infectious diseases to provide insight into the host–pathogen interactions thus justifying 
their use in vaccine development. Since vaccination is the best bet to reduce the burden posed by 
DENV, this study is aimed at developing a multi‑epitope based vaccines for dengue control. Combined 
approaches of reverse vaccinology and immunoinformatics were utilized to design multi‑epitope 
based vaccine from the sequence of DENV. Specifically, BCPreds and IEDB servers were used to predict 
the B‑cell and T‑cell epitopes, respectively. Molecular docking was carried out using Schrödinger, 
PATCHDOCK and FIREDOCK. Codon optimization and in silico cloning were done using JCAT and 
SnapGene respectively. Finally, the efficiency and stability of the designed vaccines were assessed by 
an in silico immune simulation and molecular dynamic simulation, respectively. The predicted epitopes 
were prioritized using in‑house criteria. Four candidate vaccines (DV‑1–4) were designed using suitable 
adjuvant and linkers in addition to the shortlisted epitopes. The binding interactions of these vaccines 
against the receptors TLR‑2, TLR‑4, MHC‑1 and MHC‑2 show that these candidate vaccines perfectly fit 
into the binding domains of the receptors. In addition, DV‑1 has a better binding energies of − 60.07, 
− 63.40, − 69.89 kcal/mol against MHC‑1, TLR‑2, and TLR‑4, with respect to the other vaccines. All the 
designed vaccines were highly antigenic, soluble, non‑allergenic, non‑toxic, flexible, and topologically 
assessable. The immune simulation analysis showed that DV‑1 may elicit specific immune response 
against dengue virus. Moreover, codon optimization and in silico cloning validated the expressions 
of all the designed vaccines in E. coli. Finally, the molecular dynamic study shows that DV‑1 is stable 
with minimum RMSF against TLR4. Immunoinformatics tools are now applied to screen genomes of 
interest for possible vaccine target. The designed vaccine candidates may be further experimentally 
investigated as potential vaccines capable of providing definitive preventive measure against dengue 
virus infection.
Approximately 12.5% of the world population are affected by a group of pathogens known to cause neglected 
tropical diseases (NTDs) (CDC, 2020). This diverse group of tropical infections are common among the low-
income countries in developing regions of the world. The adverse effects caused by these NTDs include but are 
not limited to impaired physical and cognitive development, and trapping the poor in a cycle of poverty and 
 disease1. Apart from condemning affected people to live with disability and stigma, these NTDs deprive children 
from attending school, threaten job security, increase the financial burden on countries due to medical cost and 
in turn negatively affecting the economy of developing  countries2–4. The ever growing list of NTDs includes, 
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parasitic helminths, bacterial, protozoan, fungal, ectoparasitic and viral diseases. The top 10 hotspots where 
NTDs dominate include sub-Saharan Africa, Asia, Oceania and the Middle  East5. For extremely pathogenic 
NTDs novel therapies are being sought. Although probably less pathogenic or less frequently encountered such 
as dengue fever, which is neglected despite an apparent increase in  prevalence6.
The endemic nature of dengue virus has been implicated in more than 100 countries notably in regions 
of Africa, Americas, Eastern Mediterranean, South-East Asia and the Western Pacific. The largest number of 
global dengue infection cases ever reported was in 2019 affecting all regions whereas dengue virus transmission 
was discovered in Afghanistan for the first time. Due to the asymptomatic and mild nature of this disease, the 
actual number of cases are under-reported with many being misdiagnosed as other febrile  illnesses7. Dengue 
is reported as the second most diagnosed cause of fever after malaria and also the dengue fever (DF) being the 
most rapidly spreading mosquito-borne  disease8. The rate of infection of dengue virus by Aedes mosquito spe-
cies (Aedes aegypti and Aedes albopictus) increases geometrically with annual infection of about 400 million and 
22,000  deaths9. Some of the symptoms include high fever accompanied by severe headache, anorexia, abdominal 
discomfort, maculopapular rash, fatigue, muscle and joint pain, unpleasant metallic taste in the mouth, loss of 
appetite, vomiting and  diarrhea10,11. The World Health Organization (WHO) classified DF into uncomplicated 
and severe DF. In addition, dengue transmission is attributed to four serotypes of the dengue virus (DENV 1–4), 
where, individuals can be infected by all the four serotypes in their lifetime.
There are several potential dengue vaccines at different stages of development in clinical trial with only one 
licensed for use. Most of these vaccines are primarily developed from the envelope proteins prM and E, which 
are expected to elicit protective immune responses in  humans13,14. Nonetheless, it is essential to consider that the 
human immune response to DENV is dominated by highly cross-reactive antibodies equipped with neutralizing 
and enhancing  activity15,16. The Dengvaxia manufactured by Sanofi Pasteur is a live, attenuated, and tetravalent 
recombinant vaccine called  ChimeriVax12. This formulation was the first vaccine to be licensed against dengue 
in the year 2015 due to its promising results obtained in various clinical  studies17. In May 2019, Dengvaxia was 
licensed and approved by the US Food and Drug Administration (FDA) in the United States in areas where den-
gue was prevalent. This vaccine is available in 19 countries, and its use is limited to for a particular age range and 
cannot be administered in Flavivírus-naïve  individual18. Its formulation consists of chimeric viruses constructed 
by infectious clone technology. Individuals who receive the vaccine and have not been previously exposed to DV 
may likely develop severe dengue if they are infected after  vaccination19,20. Although Dengvaxia was evaluated 
and licensed for human use in 20 countries, it does not contain the non-structural proteins of DENV which 
presents low protective efficacy and increases their risk of  hospitalization21. In 2018 the safety issues from the 
phase III clinical trial of Dengvaxia was  published22. Due to the increased rate of hospitalization occurring in 
seronegative vaccinated children between the age of 9–11, Dengvaxia was predicted as vaccine failures rather 
than as vaccine enhanced dengue  disease23.
Other vaccine formulations against DENV include live attenuated tetravalent vaccine for dengue (LATV), 
TAK-003, tetravalent dengue (TDEN), dengue purified inactivated vaccine (DPIV), tetravalent DNA vaccine 
against dengue (TVDV), and genetic constructs of the tetravalent vaccine formulation (V180)24. The LATV 
was developed by the National Institute of Allergy and Infectious Diseases (NIAID) using recombinant DNA 
 technology25. The formulation of this anti-dengue formulation contains the structural and non-structural DENV 
proteins and the trial study was proven to be  safe26,27. LATV is currently in phase III clinical trial. The main chal-
lenge of LATV is that it requires a significant amount of DENV2 for a balanced seroconversion and the efficacy 
is yet  unknown28. Tak-003 produced by Takeda Pharmaceutical Company Limited, is based on an attenuated 
virus and chimeric viruses constructed using recombinant DNA  technology29. Currently in phase III clinical 
trial, Tak-003 in the was shown to be safe, immunogenic, and effective against all the four DENV serotypes with 
reduced cellular immune  response30,31. Its efficacy was reported to be 80.2%. However, Tak-003 induces low 
levels of antibodies to  DENV332.
V180 is another anti-dengue potential vaccine registered under the ClinicalTrials.gov is under the phase I 
clinical trial. It is composed of the recombinant forms of the DENV envelope  glycoprotein33. Currently, V180 is 
being developed by Merck and the vaccine formulation is adjuvanted by ISCOMATRIX™34. In preclinical study, 
V180 was proven to be safe and immunogenic due to the high quality of the recombinant proteins and ISCOMA-
TRIX™ adjuvant. Nonetheless, the immunogenic properties of V180 is dependent on adjuvants and three-dose 
immunization regimen is  required35. TDEN, DPIV, and TVDV produced by the U.S. Army Medical Research and 
Materiel Command have been reported to be immunogenic, well-tolerated and safe. While DPIV and TVDV are 
in phase I clinical trial, TDEN is in phase II clinical  trial36–38. Challenges associated with these vaccines include 
general body pain, neutralizing antibody titers decrease over time, TVDV presents only envelop (E) and mem-
brane glycoprotein precursor (M) proteins and requires both adjuvant and high amount of vaccine  antigen39. 
Due to the tetravalent nature of DENV, effective vaccine, long-term surveillance for potential adverse events, 
compatibility with current vaccine schedules, cost and stability are the current challenges in the implementation 
of the DENV vaccines. Therefore, the improvement in vaccine development against dengue is much needed.
Structurally, the genome of DENV is made of 10,696 nucleotides and 10,173 of these nucleotides are responsi-
ble for the single open reading frame (ORF) which encodes a polypeptide of 3,391 amino acid  residues40. In addi-
tion to its single and positive sense RNA stranded (+ ssRNA), it encodes for both structural and non-structural 
proteins. Immunologically, DENVs are related but genetically and antigenically distinct with approximately 75% 
 relatedness41,42. DENV serotypes are subdivided according to the envelope gene responsible for incomplete cross-
defensive immunity towards other serotypes in Homo sapiens43. As perceived by the immune system, disease 
development, viral replication and antigenic determinants have been linked with DENV  proteins44,45. Therefore, 
any antigenic DENV protein sequences that is fit to elicit immune responses its host could be employed in the 
identification of vaccine for  dengue46.
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Asides palliative therapy, the treatment of both dengue and severe dengue are not specific and the mode of 
action by which the immune system react to this infection is unclear. Moreover, successful mosquito control 
measure to limit the spread of DF is still in its infant stage. As such, epitope-based vaccine development remains 
a clear solution for this infection.
In this study, several computational approaches were applied to design multiple epitope-based vaccines 
against DENV that comprises multiple epitope, which elicit the activation of cytotoxic T lymphocytes (CTLs) 
and helper T lymphocytes (HTLs). These vaccines require simple peptides that are easily chemically synthesized 
rather than pathogens. These approaches present an advantage over conventional methods of vaccine develop-
ment by reducing the chance of allergenic reactions. In addition, these methods are rapid, easy and cost-effective. 
Although, similar approaches have been widely employed for the construction of vaccines against viruses such as 
SARS-CoV-247,  Ebola48,  Zika49, and  Chikungunya50, to date, no commercial and licensed epitope-based vaccine 
are available on the market using these bioinformatics  approaches51,52.
Results
Sequence selection. In order to develop an epitope/ multi-epitope based vaccine for DEN-4, the protein 
sequences of DENV (structural and non-structural sequences) were obtained from NCBI and UniProt. The pro-
cess of component sequence selection was modified from Ali et al.53. These components are presented in Table 1. 
Their physical and chemical properties are also presented in Table 2. Structural proteins are responsible for host 
invasion and particle assembly. On the other hand, enzyme synthesis which aids viral replication and struc-
tural protein synthesis are attributed to non-structural proteins. After infection, they prompt different immune 
responses. Prior to downstream analysis, the retrieved sequences were subjected to antigenicity and transmem-
brane helices prediction, and physicochemical analysis. All the three structural proteins were confirmed anti-
genic at a threshold of 0.4. While the non-structural components NS2A, NS2B and NS4A were non-antigenic 
due to their low prediction score, NS1, NS3 and NS5 were predicted to be antigenic. With a prediction score of 
0.544, non- structural NS5 was the most antigenic viral component of DEN-4 (Table 3).
The TMHMM Server DTU Bioinformatics prediction tool revealed the position and amino acid range of the 
sequences of the selected viral components (Table 4). The capsid protein and selected sequence length of the 
envelop protein (466–471) were predicted to be localized inside the cell. All selected antigenic non-structural 
protein components and membrane glycoprotein precursor sequences were localized outside the cell.
Table 1.  Structural and non-structural protein sequences of DENV 4 retrieved from NCBI.
RefSeq Protein name Length (aa) Accession ID
NP_073286.1 Polyprotein 3387 NP_073286
NP_740313.1 Capsid protein (C) 99 NP_740313
NP_740315.1 Membrane glycoprotein precursor (M) 166 NP_740315
NP_740317.1 Envelope protein (E) 495 NP_740317
NP_740318.1 Nonstructural protein NS1 352 NP_740318
NP_740319.1 Nonstructural protein NS2A 218 NP_740319
NP_740320.1 Nonstructural protein NS2B 130 NP_740320
NP_740321.1 Nonstructural protein NS3 618 NP_740321
NP_740322.1 nonstructural protein NS4A 127 NP_740322
NP_740324.1 Nonstructural protein NS4B 245 NP_740324
NP_740325.1 RNA-dependent RNA polymerase NS5 900 NP_740325
Table 2.  Physicochemical properties of the viral protein. https:// web. expasy. org/ cgi- bin/ protp aram/ protp 
aram.
Parameters prM E NS1 NS2A NS2B NS3 NS4A NS4B NS5
Total AAs 166 495 352 218 130 618 127 245 900
Mol. w 18,709.67 53,988.10 39,635.01 24,039.33 13,939.24 69,397.18 13,910.58 26,580.16 102,969.54
Theo. pI 6.35 7.90 6.55 9.72 4.27 8.35 5.26 9.01 8.80
Ext. coeff 33,835 72,140 96,660 19,730 26,470 99,600 13,980 36,565 214,125
Half-life 1.1 30 1.1 30 1.9 1.9 1.9 1.4 30
I.I 47.04 24.64 44.12 48.82 29.02 33.53 34.42 28.62 38.21
Alip. index 75.78 80.67 67.84 131.88 116.23 78.11 132.20 105.59 71.13
GRAVY − 0.122 − 0.72 − 0.460 0.852 0.422 − 0.479 0.667 0.273 − 0.607
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Prediction of B‑cell epitope. B-cell epitopes were predicted using BCPREDS for all antigenic structural 
and non-structural protein components of DENV-4. Predicted epitopes were shortlisted on the basis of pre-
diction score, toxicity, allergenicity, antigenicity, hydrophobicity and surface accessibility. All epitopes with a 
score ≥ 0.70 were selected for vaccine design. A total of 47 epitopes were predicted for all protein components 
while only 9 epitopes satisfied the set criteria and were selected for further analysis. One epitope each was 
predicted for the capsid protein, membrane glycoprotein precursor and NS1. Although no B-cell epitope was 
predicted for the confirmed antigenic sequences of NS3, 4 and 2 B-cell epitopes were shortlisted for NS5 and 
the envelop components respectively. These selected epitopes were further validated using BepiPred for their 
structural and relative surface accessibility through NetsurfP’s default threshold. Regions of the B-cell epitopes 
(italicized) were predicted by SVMTrip with a score of 1.00 (Table 5).
T‑cell epitopes predictions and prioritization. Table 6 shows the final list of the selected epitopes for 
each of the antigenic viral components. Briefly, the selected viral components of DV were subjected to various 
MHC I and II epitopes prediction web-based servers (immune epitope database and analysis resources as well 
as the CTLPred). T cell epitopes (HTL and CTL) were ranked based on stringent in-house criteria before being 
shortlisted for downstream analysis. These rules of selection include: Good IEDB score, high conservancy, good 
binding affinity, B-cell epitope overlap, ≥ 9mer for MHC I, 15mer for MHC II, significantly antigenic/immuno-
genic and topographically accessible to membrane-bound or free antibody. For high immunogenicity, lower 
percentile ranks and  IC50 value were considered. According to these specifications, 21 epitopes each (C-2, M-3, 
E-4, NS1-1, NS3-3, and NS5-8) and (C-5, E-5, NS1-1, NS3-5, and NS5-5) were shortlisted for MHC-I and MHC 
II binders for multi-epitope based vaccine designed.
Immune receptors. The receptors considered for docking include two immune alleles (HLA-A*11-01 and 
HLA-DRB1*04-01) and two immune molecules toll-like receptors (TLR2 and TLR4). Their respective crystal-
lographic structures with PDB IDs (HLA-A*11-01: 5WJL and HLA-DRB1*04-01: 5JLZ; TLR2: 3FXI and TLR4: 
2Z7X) were retrieved from the protein data bank. Since proteins from the PDB database often lack coordinates 
for side-chains on the surface of the protein given the complexity to determine side chain coordinates from 
x-ray crystallographic data, all proteins were refined through the protein preparation wizard in Schrödinger to 
improve the overall quality of the output. These refined outputs (Fig. 1) were then used for docking analysis.
Table 3.  Antigenicity prediction of dengue virus proteins. (Threshold = 0.4 with tumor model).
Viral component VaxiJen score Probability Localization
Capsid protein 0.4938 Antigenic Mitochondria
0.4725 Antigenic Plasma membrane
Envelope protein 0.4090 Antigenic Cytoplasmic
Nonstructural protein NS1 0.4340 Antigenic Extracellular
Nonstructural protein NS2A 0.0365 Non-antigenic Plasma membrane
Nonstructural protein NS2B 0.1671 Non-antigenic Plasma membrane
Nonstructural protein NS3 0.4756 Antigenic Mito, Cytoplasmic
Nonstructural protein NS4A 0.0957 Non-antigenic Plasma membrane
Nonstructural protein NS4B 0.1549 Non-antigenic Plasma membrane
Nonstructural protein NS5 0.54368 Antigenic Cytoplasmic
Table 4.  Prediction of transmembrane helices in proteins using the TMHMM Server v2.0.
Viral component Position Amino acids
Capsid protein Inside 1–99







Nonstructural protein NS1 Outside 1–352
Nonstructural protein NS3 Outside 1–618
Nonstructural protein NS5 Outside 1–900
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Vaccine construction. From the prioritized epitopes, four vaccines were constructed, with the aim to elicit 
an immune response against DENV-4. Three different adjuvants i.e. beta defensin, L7/L12 ribosomal protein 
and HABA protein were used to construct four different vaccines. PADRE sequence is a pan HLA-DR epitope 
peptide that was used for vaccine construction to enhance their potency with minimal toxicity. The PADRE 
sequence improves the CTL response as it has the capability to bind with different MHC class-II molecules with 
high binding affinity (Wu et al., 2010). Also, appropriate linkers were used for the conjugation of the prioritized 
epitopes during the design process. The final vaccine lengths for DV1-4 were 352, 336, 336 and 400 respectively 
(Table 7).
Designed vaccine properties analysis. The various vaccine components including their specific proper-
ties are presented in Table 3. In addition to the different adjuvants used for the design, the antigenicity, aller-
genicity, toxicity and surface accessibility of these vaccines were also evaluated (Table 8). All designed vaccines 
Table 5.  Selected B-cell epitopes. The B-cell epitopes were predicted using BCPREDS web-based tool and were 
validated by BepiPred 2.0 software. Epitopes are represented as BCPREDS predicted. Green colored epitopes 
were predicted by BepiPred. Additionally, underlined amino acids are structurally coiled whereas the amino 
acids (not underlined) are structurally helix. For surface accessibility, subscripted amino acids are buried as 
against the exposed amino acids. VC viral component; Pos. position; B-score BCPred score, A-score ABCpred 
score, AT-score antigenicity score. For antigenicity prediction, the threshold was set to 0.4, which implies that 
any predicted epitope with antigenicity score ≥ 0.4 is said to be antigenic. In addition, regions of the B-cell 
epitopes predicted by SVMTrip with a score of 1.00 were italicized.
VC Pos
. 
Epitopes B-Scores AT-Score Allergenicity A-score Conservancy 
C 57 SIPPTAGILKRWGQLKKNKA 0.975 0.7003 Non-a 0.83 50% (2 /4) 













25% (1 /4) 
100% (4/4)


























25% (1 /4) 
25% (1 /4) 
75% (3 /4) 
Table 6.  Composite table of the prioritized epitopes for vaccine development. Underlined residues are 
structurally coiled whereas the amino acids (not underlined) are structurally helix. For surface accessibility, 
subscripted amino acids are buried as against the exposed amino acids. In addition, regions of the B-cell 
epitopes predicted by SVMTrip with a score of 1.00 were italicized.
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are antigenic in nature, non-allergenic and non-toxic. Furthermore, their surface accessibilities were predicted 
to be localized outside of the cell.
The physicochemical properties of these vaccines were computed using various web-based servers. Parameters 
evaluated include; solubility, amino acid composition (AAS), molecular weight Mol. W), theoretical pI (Theo. 
pI), extinction coefficient (Ext. coeff), half-life, instability index (I.I), aliphatic index (A.I), and the grand average 
of hydropathicity (GRAVY) (Table 9). DV-1 had the highest predicted solubility and Theo. pI of 0.636 and 9.87 
respectively. However, DV-4 had the highest AAs sequence and predicted ext. coeff of 400 and 59,360  M−1  cm−1 
respectively. All of the designed vaccines were found to have similar predicted half-life of 30 h. However, DV-3 
had the highest predicted aliphatic index (82.08) while DV-2 had the highest GRAVY of -0.167 among the 
designed vaccines. However, further laboratory studies are required to investigate the accuracy of these results.
Figure 1.  The prepared 3D structures of the Toll-like and Major histocompatibility complex receptors used in 
this study. (A) TLR-2; PDB ID: 2ZX; (B) TLR-4; PDB ID: 3FX1; (C) MHC class I; PDB ID: 5WJL; and (D) MHC 
class II; PDB ID: 5JLZ.
Table 7.  Predicted multi-epitope based vaccines. The distinct bold sequences are the pan HLA DR-binding 
epitope (PADRE) while the B cell epitopes are italicized.
Vaccine name Length Vaccine constructs






Dengue virus vaccine-2 (DV-2) 336
MAKLSTDELLKEMTLLELSDFVKKFEETFEVTAAAPVAVAAA GAA PAGAAVEAAEEQSEFDVILEAAGDKKIGVIKVVREIVS-
GLGLKEAKDLVDGAPKPLLEKVAKEAADEAKAKLEAAGATVTVKEAAAKAKFVAAWTLKAAA GGGSSIPPTAGILKAAY GTC 
TQSGERAAYMSYTMCSGKAAYHVQTKPGLFKAAYYVDYMPVMKGGGSKEIGRMLNILNGRKRGPGPGHGVTAMITPRSPSVEG-
PGPGAIFMTATPPGATDPFGPGPGTREEFISKVRSNAAIGGGSTLHWFRKGSSIGKMFESTYR KKTIIGRRLQRLQEEHKETWHY
Dengue virus vaccine-3 (DV-3) 336
MAENPNIDDLPLAALGAADLALATVNDLIANLRERAEETRAETRTRVEERRARLTKFQEDLPEQFIELRDKFT-
TEELRKAAEGYLEAATNRYNELVERGEAALQRLRSQTAFEDASARAEGYVDQAVELTQEALGTVASQTRAVGERA-
AKLVGIELEAAAKAKFVAAWTLKAAA GGGSVAKHERGRPLLFKAAYVTFKVPHAKRAAYVQTKPGLFKAAY RGA 
VMDIISRKGGGSLRVLSIPPTAGILKRGPGPGHKQWFLDLPLPWTAGGPGPGKSGDYVSAITQAERIGPGPGCLGKAYAQM-
WSLMYFGGGSRGSSKIRWIVERGMVKPKGK







Table 8.  Composition and assessment of the primary sequence of the multi-epitope based vaccine construct. 










B cell Length Antigenicity Allergenicity Toxicity
Surface 
accessibility
DV-1 BD 6 5 5 352 0.6136 NA NT Outside
DV-2 RP 5 4 2 336 0.6184 NA NT Outside
DV-3 HBHA 4 4 1 336 0.6945 NA NT Outside
DV-4 RP 6 8 1 400 0.6764 NA NT Outside
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Secondary structural prediction and validation of the designed vaccines. The secondary struc-
ture of the four designed vaccines were predicted by PSIPRED (Fig. 2). The structures are composed of coils, 
helixes and strands with no structural deformities. Epitopes often are found in coils and needs to be exposed. The 
sequences were then modelled by several prediction tools, including Schrödinger, to ensure accuracy (Fig. 3). 
The knowledge-based method of homology modeling of prime module was employed under Schrödinger soft-
Table 9.  Physicochemical properties of the predicted multi-epitope based vaccine construct.
Parameters DV-1 DV-2 DV-3 DV-4
Solubility 0.636 0.555 0.556 0.597
No. of amino acids 352 336 336 400
Molecular weight 37,586.86 35,295.60 36,255.51 42,958.22
Theoretical pI 9.87 9.14 9.68 9.72
Ext. coeff 55,975 29,910 40,910 59,360
Half-life 30 h 30 h 30 h 30 h
Instability Index 36.22 38.17 33.45 29.34
Aliphatic index 68.58 75.39 82.08 76.17
GRAVY − 0.376 − 0.167 − 0.331 − 0.449
Figure 2.  The secondary structures of the predicted dengue virus vaccines (PSIPRED).
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ware. For DV-1, the template ID: 2LX0 with percentage identity of 58% and expected value (e-value) of 1 ×  10–8 
was taken into consideration. For DV-2 to 4, the templates PDB IDs include 1DD3, 3J00, and 3J7Z with % 
identity of 84%, 58% and 43%, respectively. The e-values of DV-2 to 4 were 2.4 ×  10–16, 1.2 ×  10–2, and 6.0 ×  10–21, 
respectively. The coverage of these modeled templates are 37%, 39%, 35% and 30%, respectively for DV-1 to 4.
The modelled outputs were further validated by PROCHECK and ProSA-web servers prior to docking analysis 
(Fig. 4).
Docking study of the designed vaccines against the immune molecules. The interactions 
between an antigenic molecules and an immune receptors molecules are crucial to effectively transport the 
antigenic molecule and to activate immune  response54,55. Therefore, docking analysis was carried out between 
the immune receptor molecules (MCHs and TLRs) and the designed vaccines (DV-1–4) in order to investigate 
possible interactions, binding energy and poses. Docking analysis was carried out using Schrödinger as well as 
PATCHDOCK and FIREDOCK to enhance the accuracy of the prediction (Fig. 5). Schrödinger was specifically 
used to evaluate the generated poses including their solid molecular surface display (Figs. 6 and 7)56. The PATCH-
Figure 3.  The predicted multi-epitope vaccines for DENV. A) DV-1; B) DV-2; C) DV-3; and (D) DV-4 as 
modelled by Schrödinger.
Figure 4.  Validation of the modeled-predicted DENV vaccines with ProSA-Web.
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Figure 5.  Docking poses of the predicted DENV vaccines against selected immunological receptors 
(Schrodinger suite v2020-3).
Figure 6.  The solid molecular surface display of the predicted vaccines docked to the MHC class-2 receptor.
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DOCK server was used to generate the binding scores, area and ACE. The top 100 poses were refined using the 
FIREDOCK server where the global and hydrogen bond energies were generated for the docking calculation 
(Table 10). TLRs can efficiently induce the immune response after virus recognition. For TLRs, DV-1 showed the 
best binding among the four designed vaccines for TLR2 and TLR4 with binding energies of − 63.40 kcal/mol 
and − 69.89 kcal/mol. Respectively, followed by DV-4 (− 52.53 kcal/mol) and DV-3 (− 60.23 kcal/mol). For the 
MHC alleles, DV-1 and DV-4 showed the best binding interactions with HLA-A*11–01 and HLA-DRB1*04–01 
with global energies of − 60.07 kcal/mol and − 67.22 kcal/mol. respectively. For these alleles, DV-4 and DV-3 also 
showed lower energies compared to DV-2. The docking analysis showed strong interactions as well as effective 
binding between the designed vaccines and MCH1, MCH2, TLR2 and TLR4. The docking statistics are shown 
in Table 10.
Figure 7.  The solid molecular surface display of the predicted vaccines docked to the TLR-4 receptor.
Table 10.  The binding properties of the docking analysis using PATHDOCK and refined by FIREDOCK. 
H-Bond E Hydrogen bond energy; Global E Global energy, ACE Atomic contact energy *Allelic variants.
Vaccine construct Receptor Name of target Score Area H-bond E Global E ACE
DV-1
5WJL HLA-A*11–01 10,204 14.12.80 − 4.81 − 60.07 − 114.00
5JLZ HLA-DRB1*04–01 10,056 1240.30 − 2.19 − 51.02 − 140.36
3FXI TLR2 15,766 2591.40 − 3.20 − 63.40 − 33.79
2Z7X TLR4 16,202 1880.60 − 5.73 − 69.89 103.14
DV-2
5WJL HLA-A*11–01 9098 1523.60 − 1.90 − 48.11 145.04
5JLZ HLA DRB1*04–01 9072 1387.70 − 1.24 − 59.30 − 89.11
3FXI TLR2 15,784 2264.40 − 1.14 − 47.31 162.29
2Z7X TLR4 17,282 2301.00 − 1.69 − 50.15 13.11
DV-3
5WJL HLA-A*11–01 10,162 1642..20 − 2.51 − 41.64 307.70
5JLZ HLA DRB1*04–01 10,740 1373.90 − 3.83 − 63.84 − 111.34
3FXI TLR2 15,328 1816.70 − 4.09 − 45.59 182.27
2Z7X TLR4 15,214 1893.10 − 2.17 − 60.23 121.10
DV-4
5WJL HLA-A*11–01 10,444 2290.20 − 3.85 − 57.16 256.86
5JLZ HLA DRB1*04–01 10,350 1326.40 − 3.48 − 67.22 − 196.17
3FXI TLR2 15,726 2291.70 − 5.90 − 52.53 − 99.35
2Z7X TLR4 15,420 3052.30 − 6.31 − 50.39 464.55
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Optimization and in silico cloning of the designed vaccines. Efficient expression of vaccines into 
E. coli expression system is a crucial step in in silico cloning. Four vaccines (DV-1–4) were designed with the 
prioritized B-cells and T-cell predicted epitopes with appropriate adjuvants and linkers. The sequences of these 
vaccines were used as input (individually) in the Java codon adaptation tool (JCAT) in order to adapt the codon 
usage to most sequenced prokaryotic organisms. The result of this analysis shows that the DNA sequences of 
DV-1–4 were 1056, 1008, 1008 and 1200 nucleotides respectively. The observed CAIs (DV-1 = 1.0; DV-2 = 1.0; 
DV-3 = 0.99 and DV-4 = 0.98) indicated that the adapted sequences were made up of codons capable of cellular 
machinery of the target organism. Furthermore, the GC content of the improved sequences were in the range 
of 50.99% to 54.27%. This sequence information implies the efficient expression and reliability of the designed 
vaccines in E. coli. Restriction recognition sites of the restriction enzymes XhoI and NdeI were conjugated at 
the N and C-terminal of reverse translated nucleotides of DV-1–4 respectively (Fig. 8) and the final optimized 
sequences were inserted into the pET28a (+) vector in order to clone the designed vaccines using SnapGene 
software. The final lengths of the cloned plasmids were 6.352, 6.304, 6.304 and 6.396 kbp for DV-1–4, respec-
tively (Fig. 9).
Immune simulation analysis. The result of the immune simulation after injection of DV-1 is presented 
in Fig. 10. In response to several exposures of DV-1 to the host immune system, a significantly high level of 
the secondary and tertiary antibodies was observed (higher antibody detection) when compared to the pri-
mary antibodies. Consequently, rapid clearance of the antigen was detected (decrease in antigen concentra-
tion) (Fig. 10A). The different immune cell population/state count is presented in Fig. 10B–H. These immune 
cells were significantly increased with significant memory cell development; however, T-cells were gradually 
decreased after their initial increase. Similarly, an increase in the levels of cytokines were observed for IFN-ϒ 
(> 400,000 ng/ml) (Fig. 10). These observations suggest that immune memory development and the vaccine 
constructs may therefore confer immunity against the dengue virus.
Conformational stability analysis of the designed vaccines. Stability of the complex interactions 
as well as the dynamic behaviour observed between the designed vaccines and the receptors were elucidated 
through 100 ns MDs at 300 °K. The statistical parameters such as the root mean square deviation (RMSD), root 
mean square fluctuation (RMSF), and radius of gyration (rGyr) were used to probe the system for stability and 
structural adjustment of the vaccine in the binding domains of the selected receptor (Fig. 11A–D). As a measure 
of the distance between the Cα atoms of superimposed proteins, RMSD was used to evaluate the stability of 
DV-1 in the binding domain of TLR4 (Fig. 11B). Residual flexibility of DV-1-TLR4 was investigated by RMSF 
(Fig. 11C) in order to determine the extent and effect of contact deviation on the binding of DV-1 to TLR4. The 
average RMSF detected for the system was 1.2 Å. In addition; rGyr was used to characterize the secondary ele-
ments regular packing in the 3D structure of the DV-1-TLR4 complex and to evaluate complex compactness. 
The rGyr provides effective information on the tendency of protein structures to expand during  MDs57. At the 
time of simulation, the rGyr starts with a sudden increase of 4 ns and remained constant with an average value 
of 5.98 Å (Fig. 11D). The higher the rGyr the less compact the protein, with less folded stability. Interestingly, the 
rGyr profile of the system is consistent with the RMSD and RMSF profiles for complex  fluctuation58.
Figure 8.  The linear vaccine constructs with XhoI and NdeI sites. (A) DV-1, (B) DV-2, (C) DV-3, and (D) DV-4 
(SnapGene software).
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Discussion
The use of immunoinformatics approaches in the construction of potent vaccines against various microorgan-
isms especially viruses, are becoming increasingly acceptable as the first line of vaccine development. In recent 
years, immunoinformatics-guided approaches have been employed in the design of epitope-based subunits for 
SARS-CoV-259–64. Kar and  Srivastava65 also identified potential vaccine candidates against Theileria parasites 
and the T-cell epitope vaccine candidate for parasitic helminth  infection66. Dengue is a mosquito-borne viral 
infection caused by different serotypes of DENV. These serotypes (DENV-1–4) cross-react immunologically 
with each  other67. On a global scale, about three billion people are susceptible to DENV infection, of which 
approximately 96 million cases occur  annually68. Individuals with primary infection are highly prone to develop 
dengue hemorrhagic fever and dengue shock syndrome during secondary infection due to antibody-dependent 
 enhancement69,70. To date, there is no specific treatment for dengue fever and the main preventive measure is 
by vaccination in order to reduce the burden of the disease. Hence, this study aimed at designing novel multi-
epitope based DENV vaccine candidates capable of evoking immune responses in DENV infected individuals 
using computational approaches. Epitope-based vaccines have potential advantages over conventional vaccines 
and they have received considerable attention in recent years.
DENV protein components were retrieved and used for the multi-epitope based design of dengue vaccine 
in this study. The selected components were subjected to physical and chemical properties prediction prior to 
antigenic determination of the sequences. Using the threshold of 0.4, the viral components were classified into 
antigens and non-antigens using the tumor model of VaxiJen (VaxiJen v2.0). Scores below this threshold were 
classified as non-antigen and discarded. For accurate component selection, the localization and transmembrane 
helices of the protein sequences were further determined. This process ascertains the suitability of candidate 
Figure 9.  In silico restriction cloning of the codon optimized final designed vaccines in the pET-28a (+) vector 
between the XhoI (158) and NdeI (238) restriction enzyme sites (SnapGene software). The final constructs can 
further be expressed in E coli (strain K12) for efficient vaccine production.
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vaccine selection for experimental validation in vaccine development  process71,72. The final result of all the 
structural proteins and NS1, NS3, and NS5 from the non-structural proteins were considered for epitope-based 
vaccine design in this study. Furthermore, the B and T-cell epitopes were predicted from these antigenic viral 
components. A good vaccine should be able to induce immunity through the antigen with a durable adaptive 
immunity. A total of 21 antigenic and non-allergenic epitopes were predicted for both MHC classes, while nine 
antigenic, non-toxic and non-allergenic epitopes were predicted for the B-cells. The CTL epitopes are responsible 
for developing durable immunity capable of eliminating circulating virus and infected  cells73. On the other hand, 
HTL epitopes are associated with the production of both humoral and cellular immune responses. These epitopes 
elicit a  CD4+ helper response for the generation of protective  CD8+ T-cell memory and activation of B-cells74.
The homology modeling of all the predicted multi-epitope vaccines were predicted by Schrödinger and 
structurally confirmed by three web-based protein structural prediction tools  (Phyre2, RaptorX, and SCRATCH 
predictions). The predicted 3D structures of the multi-epitope vaccines were validated using PROCHECK at 
PDBSum Generate server and ProSA-web. The result of the predicted structural analysis by PROCHECK server 
is a Ramachandran plot. This plot gives information about the torsional angles (phi (φ)and psi (ψ)) of the resi-
dues contained in the input PDB file. The statistics confirmed that approximately 90% of the predicted vaccine 
residues are in both the most favoured and additional allowed regions while only few residues were detected in 
the generously allowed and disallowed regions. The model structures were further queried for potential errors 
by ProSA-Web. This software tool provides a graphical output of the overall and local model quality based on 
the input and Z-score of the predicted model. The modeled protein structures of Yadav et al.75 were reported 
to be − 5.98 kcal/mol and 6.66 kcal/mol for template and target, respectively. In addition, an investigation of 
immunogenic properties of Hemolin using an immunoinformatic approach, showed that the Z-score of the 
modeled protein was − 7.08 kcal/mol76. With Z-scores of − 5.26 kcal/mol., − 9.5 kcal/mol and − 2.11 kcal/mol, 
Figure 10.  Immunogenic potential of the designed vaccine (DV-1). In response to the exposure of DV-1 
after three injections, (A) production of immunoglobulins (B) active B-cell populations/state; (C) plasma 
B-lymphocytes and their isotypes per state; (D) helper T-cell population/state; (E) cytotoxic T-cell population/
state; (F) reduction in the level of T regulatory cells; (G) dendritic cell population per state; (H) activity of 
macrophage population/state; (I) cytokine level and interleukins (smaller plot) in different states with the 
Simpson index (dotted line). All units are in cells/mm3 in three subsequent immune responses.
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Droppa-Almeida et al.77, Rekik et al.78, and Hashemzadeh et al.79 concluded that the predicted 3D structures 
were reliable and of good quality. The overall model quality suggests the qualities of X-ray crystallography 
with Z-score of − 4.78, − 5.48, − 3.29, and − 4.24 kcal/mol. for the predicted DV-1-DV-4 vaccines, respectively. 
Overall the results of the validation tools provide evidence that the predicted vaccine structures are acceptable 
and of good quality. Therefore, the 3D-structures of the predicted vaccines are reliable and were considered for 
downstream analysis.
Molecular docking is a crucial tool employed in the field of Bioinformatics to explore specific interactions 
and binding affinities of ligands towards selected receptors based on the lock and key mechanism. In the field 
of immunoinformatics, protein–protein docking is usually employed to investigate the best, stable and effective 
vaccine through their poses, interacting atoms and their binding energies. This procedure was used to examine 
the best possible vaccine construct(s) against the MHC alleles (HLA-A*11–01 and HLA-DRB1*04–01) as well 
as the immune molecules (TLR2 and TLR4). Several immunoinformatics studies have shown the importance 
of these receptors in the production of an effective immune  response80–83. TLRs have a significant function in 
innate immunity such as immune activation and adaptive immune response. Also, the involvement of TLR2 
and TLR4 were previously investigated in the recognition of viral structural proteins leading to inflammatory 
cytokine  production84. The docking calculation between the designed constructs (DV-1–4) and the receptors 
(MHCs and TLRs) showed that the designed vaccines perfectly fit into the binding pockets of the receptors, and 
therefore, the vaccines may generate stable immune responses. Due to the global energies of the DV-1 and its 
excellent performance, it was considered for MDs study.
In silico cloning was carried out in a pET28a (+) vector after codon optimization by the JCAT web server in 
order to avoid codon  bias85. The CAIs and the GC content of the optimized nucleotides were within the accepted 
Figure 11.  Molecular dynamics simulation of (DV-1-TLR-4 complex at 100 ns (ns). (A) Molecular dynamics 
trajectory (system set-up for the simulation), (B) Root Mean Square Deviation of docked complex shows very 
minimal deviation which reflects the stable microscopic interaction between DV1 and TLR4 molecule (C) 
RMSF-Root Mean Square Fluctuation plot of docked protein complex side chain fluctuation in plot generates 
peak which reflects the flexibility of side chain of docked protein complex. (D) Time evolution of the radius of 
gyration (rRyr) during 100 ns of MD simulation.
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ranges of 0.8–1.0 and 30–70% respectively. These data confirmed that the designed constructs were reliable with 
efficient expression in the E coli strain K12.
C-ImmSim is a data-driven immune prediction algorithm and an agent-based simulator of the immune 
response previously used to study the immunogenic potentials of predicted  vaccines86. This algorithm simulates 
the major functional mammal system components (bone marrow, thymus and lymph node). Since a potent 
vaccine must imitate the natural immunity induced by antigen with the production of long-lasting adaptive 
immunity, the response of the immune cells (HTL, CTL, B-cells, dendritic cells, immunoglobulins and cytokines) 
were reported against the designed vaccines. Immune simulation with DV-1 was predicted to trigger IgG, IgM, 
B-cell, T-cell and cytokines. Similar to the results of previous immunoinformatics vaccine designed  studies87–89, 
the designed vaccines may offer protection against DENV.
The stability of the complex (DV-1-TLR4) was validated by performing a 100 ns at 300° Kelvin MDs using the 
Schrödinger software package. OPLS_2005 force field and a predefined solvent model of TIP-3P was chosen for 
the calculation. Furthermore, NaCl was added as  (Na+ and  Cl−) and the final salt concentration was 0.15 M in 
order to simulate the background salt at psychological conditions.From the result obtained, a slight fluctuation 
of TLR4-vaccine complex was observed from the start of the simulation period to about 300 ns after which there 
was no major fluctuation in the RMSD profile of the complex. The RMSF profile showed the presence of a highly 
fluctuating N-terminal region at the beginning of the simulation. This result was consistent with previous studies 
where immunoinformatics of vaccine–receptor complex stabilization was achieved within a similar time-scale 
using  MDs59,73,90,91. The rGyr measures the ’extendedness’ of a ligand, and is equivalent to its principal moment 
of inertia. The rGyr of the DV-1-TLR4 complexes ranged between 5.5 Å to 6.1 Å. This change in rGyr reveals 
the compactness of the vaccine construct-TLR4 complexes. This result implies that the designed vaccines can 
strongly interact with immune receptors.
Limitations. This study highlighted an alternative vaccine approach based on multi-epitope construction 
of the protein components of dengue genome to handle antigenic complexity. Although the predicted vaccines 
were recommended based on immunoinformatics strategies and believed to be immunogenic, the extent of pro-
tection from dengue infection is unknown. Immunoinformatics approaches are extremely useful to perform in 
silico studies and can guide laboratory experiments contributing to save time and money. Nonetheless, the next 
phase is to carry out in vitro immunological assays to validate the predicted vaccines, determine their immu-
nogenicity, and further devise challenge-protection preclinical studies to eventually certify these approaches.
There are some limitations to this current study. First, challenges such as standard benchmark, insufficient 
prediction methods, and unavailability of precise datasets for different computational analysis are associated 
with immunoinformatics approach. Secondly, little is known about the pathogenic entry and specific immune-
bypass mechanism of dengue within the human host. With this knowledge, the vaccine could be developed more 
effectively and efficiently to control and/or prevent the pathogenesis of dengue. Thirdly, the proposed vaccine 
constructs await experimental investigated through in-vitro and in-vivo bioassays to demonstrate its safety, 
efficacy, and immunogenicity against dengue by producing an active immunological memory.
On a whole, the application of these results is pending validation in the wet lab experimental models.
Methodology
Figure 12 illustrates the stepwise flow of the methodology followed to design a vaccine against DENV.
Sequence retrieval. All the protein components of DENV 1–4 were retrieved from the virus pathogen 
resource (VIPR) database at https:// www. viprb rc. org/ brc/ home. spg? decor ator= vipr and confirmed with NCBI. 
These protein components include: the structural proteins (Capsid protein (C), membrane glycoprotein precur-
sor (M), and envelop protein (E)) and the 7 non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and 
NS5). A single file containing all the sequences was generated in FASTA format.
Protein selection for vaccine preparation. The complete amino acid sequences of the proteins were 
retrieved from the NCBI database in the FASTA format. The proteins were subjected to signal peptide analyses 
using SignalP 4.1 server (http:// www. cbs. dtu. dk/ servi ces/ Signa lP/) to discriminate classical secretory and non-
secretory proteins. SignalP integrates a prediction of cleavage sites and signal/non-signal peptide predictions 
based on a combination of several artificial neural  networks92 signal was reported to outperform other predictors 
in benchmark  tests93. Localization predictions were conducted using DeepLoc (http:// www. cbs. dtu. dk/ servi ces/ 
DeepLoc/), a template-free algorithm that uses deep neural networks to predict protein subcellular localization 
using only sequence information with good  accuracy94.
Multiple sequence alignment and antigen selection. The NCBI BLAST program at https:// blast. 
ncbi. nlm. nih. gov/ Blast. cgi was used to identify highly conserved sequences of the DV. In addition, multiple 
sequence alignment was achieved using the Multalin server at https:// www. multa lin. toulo use. inra. fr/ multa lin. 
The antigenicity of the viral components (structural and non-structural) were evaluated using VaxiJen 2.0 server 
(http:// www. ddgph armfac. net/ vaxij en/ VaxiJ en/ VaxiJ en. html95. Finally, the most highly conserved sequences 
and antigenic peptides were selected for downstream analysis.
Allergenicity prediction. Allergenicity prediction is a critical step in therapeutics and bio-pharmaceuti-
cals due to their involvement in foods and/or food products. Sequence identity of known allergens is important 
for predicting the cross-reactive potential of novel proteins and their resistance to pepsin digestion and glyco-
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sylation status is used to evaluate denovo allergenicity  potential96. AllerTOP v2.0 is a bioinformatics tool and 
web-based server used for protein allergenicity prediction in this study. As outlined by Dimitrov et al.97, this tool 
(https:// www. ddg- pharm fac. net/ Aller TOP/ index. html) uses an auto cross covariance transformation of protein 
sequences into uniform equal-length vectors. The method was previously applied to quantitative structure–
activity relationship studies of peptides with different lengths using five descriptors such as hydrophobicity, 
molecular size, helix-forming propensity, relative abundance of amino acids and β-strand forming  propensity98.
Antigenicity. VaxiJen is a web-based server for prediction of protective antigens, tumour antigens and 
subunit  vaccines95. This server accessed at http:// www. ddg- pharm fac. net/ vaxij en/ was used to determine the 
best antigenic protein components and to identify epitopes from DENV-4. The viral components’ sequences, 
predicted epitopes, and constructed vaccines were used as input with ‘tumor’ as selected organism target at a 
threshold of 4.0.
B‑cell epitope prediction and selection. The B-cell epitopes were predicted using the BCPreds server 
at http:// ailab. ist. psu.edu/bcpred/. This server uses a novel kernel method for predicting linear B-cell epitopes. 
The epitope length was kept at 20 amino acids with 75% sensitivity. The use of multiple tools in epitope predic-
tion has been reported to improve the rate of true positives in epitopes  prediction99. Therefore, other prediction 
servers such as IEDB analysis Resource (http:// tools. iedb. org/ popul ation)100 and the BepiPred-2.0 web server 
(http:// www. cbs. dtu. dk/ servi ces/ BepiP red/) were used for validation. The method employed by BepiPred-2.0 is 
more superior to other available tools for sequence-based epitope prediction based on the epitope data derived 
from solved 3D structures and a large collection of linear epitopes downloaded from the IEDB database. In 
addition, the proteins were subjected to linear epitope prediction using ABCpred at https:// webs. iiitd. edu. in/ 
ragha va/ abcpr ed/ index. html to compute ABCpred epitope scores at a threshold of 0.5. At this threshold, the tool 
shows 65.93% accuracy with equal sensitivity and specificity using a window length of 16. Finally, the server, 
SVMTrip at http:// sysbio. unl. edu/ SVMTr iP/ predi ction. php was used to improve the prediction performance for 
the predicted B-cell epitopes.
T‑Cell epitope prediction analysis. Following the combined methods of Shey et al.101, Ali et al.53 and 
Ullah et al.48, the IEDB epitope analysis resource at https:// www. iedb. org/ home_ v3. php was used to predict the 
MHC class I and MHC class II binding epitopes. Briefly, the MCH class I restricted  CD8+ cytotoxic T lympho-
cyte (CTL) epitopes from the antigenic viral components of DENV-4 were predicted using the NetMHCpanEL 
4.0 prediction method for HLAA*11–01 allele. The result of this method was further subjected to the SMM 
method in order to prioritize the selected CTL epitopes using the  IC50 threshold of 500 nM and percentile ranks 
of ≤ 0.2. In addition, the 15-mer MCH class II-restricted  CD4+ helper T lymphocyte (HTL) epitopes were pre-
dicted using the NetMHCIIpanEL 4.0 prediction method for HLA DRB1*04–01 alleles. The predicted classes 
of the MHCs were further screened for antigenicity, non-allergenicity, non-toxicity, highly conservancy and 
transmembrane topology.
Figure 12.  Overview of the study design.
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Toxicity and transmembrane topology analysis. ToxinPred is an in silico software tool used for the 
prediction as well as the design of both toxic and non-toxic peptides. This tool predicts the toxicity of the epitopes 
according to their physicochemical properties of the input sequences. With the default settings, the predicted 
sequences were used as input in order to determine their toxicity. Epitopes that were not predicted as allergens 
by AllerTOP were subjected to toxicity analysis by the ToxinPred webserver at http:// crdd. osdd. net/ ragha va/ 
toxin pred/. All the peptides predicted as toxic were discarded. In addition, the transmembrane topology experi-
ment of the viral component and the predicted epitopes were evaluated using the TMHMM v2.0 server (http:// 
www. cbs. dtu. dk/ servi ces/ TMHMM/). This tool is user-friendly for determining the transmembrane topology of 
epitopes using their sequences as  input102.
Analysis of the physicochemical properties and construct solubility. The physicochemical prop-
erties of the viral components and the constructed vaccines were predicted by ExPASy ProtParam at https:// 
web. expasy. org/ protp aram/103. Characteristics such as number of amino acids, molecular weight, theoretical pI, 
half-lives, instability indexes, extinction coefficient, aliphatic index and grand average of hydropathicity were 
 evaluated104. Protein-Sol (https:// prote in- sol. manch ester. ac. uk/) was used to evaluate the solubility of the multi-
epitope based  vaccines105.
Epitope conservancy analysis. The predicted epitopes were subjected to conservancy analysis in order 
to predict the degree of similarity within the serotypes of dengue virus at sequence identity threshold of ≥ 80%. 
Using the IEDB analysis resource at http:// tools. iedb. org/ conse rvancy/, each of the epitopes predicted were used 
as input against all the serotypes of dengue (DENV 1–4).
Vaccine construction. Vaccine construction requires three requisite elements in order to create an efficient 
molecule capable of eliciting an immune response. These elements include the identified epitopes (the B- and the 
T-cell epitopes), adjuvants and the spacer sequences. The predicted epitopes from the DENV-4 were selected for 
the final vaccine construction after the in-house screening processes. In order to amplify the immune system, 
molecules with immunomodulatory properties were added to the vaccine constructs as safe vaccine adjuvants. 
The adjuvants were connected to the epitopes using the rigid linker EAAAK. The glycine-proline rich GPGPG 
linkers were used to space the B-cell and HTL epitopes. In addition, the CTL epitopes were linked using an 
effective and flexible linker AAY. To prevent the polymorphism of HLA-DR molecules, the Pan DR T Helper 
Epitope (PADRE epitope) was introduced to the final vaccine sequences. The sequence order of the final vaccines 
are as follows: Adjuvant-Rigid linker (EAAAK)-PADRE-GGGS-BCL-flexible linker (KK)-BCL-flexible linker 
(GPGPG)-HTL-flexible linker (GGGS)-HTL-flexible linker (AAY)-CTL. Four vaccines were constructed with 
three adjuvants namely heparin-binding hemagglutinin (HBHA), beta defensin, and ribosomal protein L7/L12 
for the vaccines DV-1 to 4 respectively.
Homology modelling of the predicted epitopes. The 3D structures of the epitopes and the designed 
vaccines were modeled using the structure prediction wizard of prime module in the Schrodinger suites v2020-3 
using the Maestro v12.3 software interface. Since the process of constructing a 3D atomic-resolution model is 
based on the principle that evolutionary related proteins share similar sequence and protein structures, homol-
ogy modeling therefore, relies on high quality sequence alignment and template structure (knowledge-based 
method of modeling). The predicted epitopes and designed sequences were used as input individually in FASTA 
format followed by the BLAST homology search. Homology modeling steps such as template recognition and 
initial alignment, alignment correction, backbone generation, loop and side chain modeling, model optimiza-
tion and validation were all performed on the 3D predicted models. In addition, the online protein structure pre-
dictions; Protein Homology/analogY Recognition Engine V 2.0  (Phyre2) at http:// www. sbg. bio. ic. ac. uk/ phyre2/ 
html/ page. cgi? id= index, RaptorX at http:// rapto rx. uchic ago. edu/ Conta ctMap/, and SCRATCH protein predic-
tor at http:// scrat ch. prote omics. ics. uci. edu/ were used to remodel and ascertain the modeled 3D structures of 
the designed vaccines.
Secondary structure prediction. PSIPRED V3.3 at http:// bioinf. cs. ucl. ac. uk/ psipr edtest was utilized to 
predict the secondary structures of the designed vaccines using their primary sequences as input. PSIPRED is 
a simple and accurate 2D structure prediction method, incorporating two feed-forward neural networks that 
performs an analysis on output obtained from PSI-BLAST (Position Specific Iterated-BLAST)106.
Structural validation of the modeled vaccines. Following the modified method of Saha and  Prasad107, 
the PDBSum module in the EMBL-EBI database (https:// www. ebi. ac. uk/) and ProSA-Web at https:// prosa. servi 
ces. came. sbg. ac. at/ prosa. php were used to analyze the designed vaccine constructs before and after minimiza-
tion and refinement in order to validate their  purities108. Specifically, the PDBSum Generate at http:// www. ebi. ac. 
uk/ thorn ton- srv/ datab ases/ pdbsum/ Gener ate. html use the PDB files of the prepared constructs after homology 
modeling and preparation as input to evaluate purity using the PROCHECK and produces a graphical output in 
the form of a Ramachandran  plot109. The higher the percentage of atoms in the most favored region the greater 
the resolution and purity and the models can be used for molecular docking calculations.
Receptor selection. It is crucial for designed vaccines to interact with immune cells in order to confer the 
stability of the immune response. The molecular docking calculation study was performed to investigate these 
interactions using the Major histocompatibility complex (MHCs) receptors as well as the Toll-like receptors 
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(TLRs). Following previously methods of receptor  selections64,101,110, the crystal structures of MHC class I allele 
(HLA-A*11–01) and MHC class II allele (HLA DRB1*04–01) with PDB IDs, 5WJL and 5JLZ were retrieved 
from the Protein Data Bank (PDB) at https:// www. rcsb. org/. In addition, the 3D structure of TLR4 dimer and 
TLR2 (PDB ID: 3FXI and PDB ID: 2Z7X) were retrieved for additional docking purposes. These proteins were 
refined, minimized and optimized using the protein preparation wizard in the Schrodinger suite and were fur-
ther considered for molecular docking analysis with the multi-epitope constructed  vaccines111.
In silico docking calculation. To inspect the binding affinity of the modeled vaccines to MHCs and TLRs 
molecules, the designed vaccines were docked against the selected receptors using the Prime protein–protein 
docking module in  Schrodinger112. The binding score and the atomic contact energy were analyzed using the 
PATCHDOCK server at https:// bioin fo3d. cs. tau. ac. il/ Patch Dock/ php. php while the refinement of the generated 
poses including the global energy were carried out using the FIREDOCK server at http:// bioin fo3d. cs. tau. ac. il/ 
FireD ock/ php. php.
Optimization of designed vaccine candidate. Reverse translation and codon optimization were per-
formed using the Java Codon Adaptation Tool (JCat) server (http:// www. jcat. de/) in order to express the multi-
epitope vaccine construct in a selected expression  vector113. Codon optimization was performed in order to 
express the final vaccine construct in the E. coli (strain K12) host, as codon usage of E. coli differs from that of 
‘homo sapiens’, where the sequence of the final vaccine construct is derived. In the additional options section, 
the ‘avoid the rho-independent transcription termination’, ‘avoid prokaryote ribosome binding site’, and ‘avoid 
restriction enzymes cleavage sites’ were all checked. The JCat output includes the codon adaptation index (CAI) 
and GC content (%), which can be used to assess protein expression levels. CAI provides information on codon 
usage biases; the ideal CAI score is 1.0 but > 0.8 is considered a good  score114. The GC content of a sequence 
should range between 30–70%. GC content values outside this range suggest unfavorable effects on transla-
tional and transcriptional  efficiencies53. To clone the optimized gene sequence of the final vaccine constructs 
in E. coli pET-28a (+) vector, XhoI and NdeI restriction sites were added to the N and C-terminals of the DNA 
sequences of the predicted vaccines, respectively. Finally, the optimized DNA sequences (with restriction sites) 
were inserted into the pET-28a (+) vector using SnapGene tool to ensure vaccine expression.
Immune simulation of the designed vaccines. In order to understand the immune system relative 
to the predicted vaccines, C-ImmSim at http:// 150. 146.2. 1/C- IMMSIM/ index. php? page=1 were employed to 
assess the molecular binding of immune complexes. The principle of operation of this server is based on the 
position-specific scoring matrix and machine learning approaches to predict subunit vaccine and binding inter-
actions. Following the clinical vaccine recommended  procedures115,116, and immune simulation methods previ-
ously  reported89,101,117,118, three injections were administered for a total of 1000 steps of simulation using the 
designed vaccine sequences as input.
Molecular Dynamic simulation (MDs). MDs of the designed vaccines of the immunogenicity were char-
acterized by the system build and molecular dynamic Desmond package in Schrödinger. Prior to simulation, the 
docked complexes were prepared using the system builder module in Maestro v12.4. The optimized potentials 
for the liquid simulations OPLS-2005 force field were used to determine the receptor interactions which were 
solvated with the simple point charged (TIP-3P) water  model119,120. The orthorhombic water box was used to 
create a 10 Å buffer region between the atoms on the receptors and box sides. The volume of the box was mini-
mized and the overall charge of the system was neutralized by adding  Na+. The temperature and pressure were 
kept constant at 300° Kelvin and 1.01325 bar using the Nose–Hoover  thermostat121 and Martyna–Tobias–Klein 
barostat methods. The simulations were performed using NPT ensemble by considering the number of atoms, 
pressure and timescale and the simulation time at 100 ns. The MD results were analyzed by simulation interac-
tions diagram module and MS-MD trajectory analysis.
Conclusion
In this study, immunoinformatics approaches were employed in the development of potential vaccine candi-
dates against DENV considering their ease of use in experimental investigations. Since the only viable defense 
for DENV infection is a vaccine; four potential vaccines were designed and predicted to elicit specific immune 
responses in individuals with dengue infection. The results of this study are based on computational approaches. 
Therefore, it is required that both in-vivo and in-vitro laboratory experiments be carried out to ascertain the 
results of this study.
Data availability
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